JP2003515611A5 - - Google Patents

Download PDF

Info

Publication number
JP2003515611A5
JP2003515611A5 JP2001542722A JP2001542722A JP2003515611A5 JP 2003515611 A5 JP2003515611 A5 JP 2003515611A5 JP 2001542722 A JP2001542722 A JP 2001542722A JP 2001542722 A JP2001542722 A JP 2001542722A JP 2003515611 A5 JP2003515611 A5 JP 2003515611A5
Authority
JP
Japan
Prior art keywords
eplerenone
solvate
shows
ethyl ketone
methyl ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001542722A
Other languages
English (en)
Japanese (ja)
Other versions
JP4219105B2 (ja
JP2003515611A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/030178 external-priority patent/WO2001041535A2/en
Publication of JP2003515611A publication Critical patent/JP2003515611A/ja
Publication of JP2003515611A5 publication Critical patent/JP2003515611A5/ja
Application granted granted Critical
Publication of JP4219105B2 publication Critical patent/JP4219105B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

JP2001542722A 1999-12-08 2000-12-04 エプレレノン結晶形 Expired - Fee Related JP4219105B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US16960899P 1999-12-08 1999-12-08
US16955699P 1999-12-08 1999-12-08
US16968399P 1999-12-08 1999-12-08
US16970799P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US60/169,608 1999-12-08
US60/169,683 1999-12-08
US60/169,807 1999-12-08
US60/169,556 1999-12-08
US60/169,707 1999-12-08
US60/169,639 1999-12-08
PCT/US2000/030178 WO2001041535A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2006238694A Division JP2007016043A (ja) 1999-12-08 2006-09-04 エプレレノン結晶形

Publications (3)

Publication Number Publication Date
JP2003515611A JP2003515611A (ja) 2003-05-07
JP2003515611A5 true JP2003515611A5 (https=) 2006-01-05
JP4219105B2 JP4219105B2 (ja) 2009-02-04

Family

ID=27558586

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001542722A Expired - Fee Related JP4219105B2 (ja) 1999-12-08 2000-12-04 エプレレノン結晶形
JP2006238694A Pending JP2007016043A (ja) 1999-12-08 2006-09-04 エプレレノン結晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2006238694A Pending JP2007016043A (ja) 1999-12-08 2006-09-04 エプレレノン結晶形

Country Status (18)

Country Link
US (1) US20090149431A1 (https=)
EP (1) EP1175434A2 (https=)
JP (2) JP4219105B2 (https=)
KR (1) KR100584104B1 (https=)
CN (1) CN100413881C (https=)
AR (1) AR074665A2 (https=)
AU (1) AU2041101A (https=)
BR (1) BR0008054A (https=)
CA (1) CA2362845A1 (https=)
CO (1) CO5280205A1 (https=)
EA (1) EA008449B1 (https=)
HU (1) HUP0201457A3 (https=)
IL (2) IL144757A0 (https=)
MY (1) MY143571A (https=)
NO (1) NO20013857L (https=)
NZ (1) NZ513962A (https=)
PE (1) PE20010918A1 (https=)
WO (1) WO2001041535A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
ES2566934T3 (es) 2010-05-10 2016-04-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN104844681B (zh) * 2014-02-13 2016-06-01 合肥久诺医药科技有限公司 一种l晶型依普利酮的精制方法
WO2017064121A1 (en) 2015-10-13 2017-04-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
CN113173968A (zh) * 2021-03-19 2021-07-27 江苏康思尔医药科技有限公司 一种依普利酮的纯化方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5981744A (en) * 1995-12-11 1999-11-09 G. D. Searle And Co. Processes for preparation of 9,11-epoxy steroids and intermediates useful therein
PT944644E (pt) * 1996-12-11 2003-02-28 Searle & Co Processos para a preparacao de esteroides 9,11-epoxi e intermediarios uteis para esse efeito
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Similar Documents

Publication Publication Date Title
Zhu et al. Influence of water activity in organic solvent+ water mixtures on the nature of the crystallizing drug phase. 2. Ampicillin
JP2003515611A5 (https=)
JP2003516414A5 (https=)
HK1202531A1 (en) Hydrates of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
AU2007256432A1 (en) Crystalline forms of 11 beta-(4-acetylphenyl)-20,20,21,21,21-pentafluor-17- hydroxy-19-nor-17alpha-pregna-4,9-dien-3-one
TWI585092B (zh) 晶狀（１ｒ，４ｒ）－６’－氟基－Ｎ，Ｎ－二甲基－４－苯基－４’，９’－二氫－３’Ｈ－螺［環己烷－１，１’－吡喃［３，４，ｂ］吲哚］－４－胺
JP2007016043A5 (https=)
WO2006053781A1 (en) Process of making crystalline aripiprazole
JPH0377199B2 (https=)
US6552189B2 (en) Anhydrous mirtazapine crystals and process for preparing the same
EA005623B1 (ru) НОВЫЕ ТВЕРДЫЕ ФОРМЫ МЕЗОПРОГЕСТИНА-11β-[4E-(ГИДРОКСИИМИНОМЕТИЛ)ФЕНИЛ]-17α-МЕТОКСИМЕТИЛ-17β-МЕТОКСИЭСТРА-4,9-ДИЕН-3-ОНА
RU2278118C2 (ru) Способ получения кристаллических форм i или v каберголина, способ получения сольватированной формы v каберголина
JP4219105B2 (ja) エプレレノン結晶形
WO2018008219A1 (ja) アジルサルタン中間体、アジルサルタン、及びこれらの製造方法
CN1568305A (zh) 新的无水结晶形式的加巴喷丁
WO2003078392A2 (en) Process for preparing crystalline form i of cabergoline
Jorio et al. High-temperature phase transitions in incommensurate Rb2WO4
US7393964B2 (en) Process for the preparation of norelgestromin
WO2014118180A1 (en) Crystalline form of linaclotide
WO2003006421A1 (en) Method for purifying n2-(1(s)-ethoxycarbonyl-3- phenylpropyl)-n6-trifluoroacetyl-l-lysine
JP2005517020A (ja) ベツリン酸製造の改良方法
JP2736169B2 (ja) Ｎ−Ｔ−ブチル−アンドロスト−３，５−ジエン−１７β−カルボキサミド−３−カルボン酸多形体Ａ
JP2003073334A (ja) ２−エチル−２−アダマンチルメタクリレート結晶粉末
Green et al. Structural phase transformations in C70
Criadoa et al. Influence of Grinding and Atmosphere on the Crystallization of ZrO2 gel